Warner-Lambert’s D.C. office
Executive Summary
P. Vincent LoVoi to join firm at the end of July as head of the Washington office. As a previous legislative director for Rep. Synar (D-Okla.), LoVoi was involved with the development of the patent provisions (Title II) of the Waxman/Hatch Act. Currently an attorney with the D.C. firm Akin Gump Strauss Hauer & Feld, LoVoi's title at Warner-Lambert will be VP-government affairs/legislative counsel. LoVoi replaces W. Bradford Gray, who left the firm in June.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip